LANCET ONCOLOGY

Scope & Guideline

Pioneering insights in the fight against cancer.

Introduction

Welcome to the LANCET ONCOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of LANCET ONCOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1470-2045
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2000 to 2024
AbbreviationLANCET ONCOL / Lancet Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

LANCET ONCOLOGY focuses on disseminating high-quality, peer-reviewed research in the field of oncology, emphasizing the latest advancements in cancer treatment, prevention, and patient care. The journal aims to address significant challenges in cancer research and clinical practice, with a commitment to improving outcomes for cancer patients globally.
  1. Innovative Cancer Therapies:
    The journal publishes studies on novel therapeutic approaches including immunotherapy, targeted therapies, and combination treatments across various cancer types.
  2. Patient-Centered Outcomes:
    Research focusing on health-related quality of life, patient-reported outcomes, and the psychosocial aspects of cancer care is a significant area of interest, emphasizing the importance of patient perspectives in treatment efficacy.
  3. Clinical Trials and Methodological Advances:
    LANCET ONCOLOGY features a wide range of clinical trials, from phase 1 to phase 3, and promotes methodological innovations that enhance trial designs, patient recruitment, and outcome assessments.
  4. Global Cancer Burden and Health Disparities:
    The journal addresses disparities in cancer care and outcomes, particularly in low- and middle-income countries, highlighting global health initiatives and the need for equitable access to cancer treatments.
  5. Translational Research and Precision Medicine:
    Research that bridges laboratory findings with clinical applications, focusing on biomarkers and genomic profiling to tailor cancer treatments to individual patients.
LANCET ONCOLOGY is at the forefront of addressing emerging trends and themes in oncology research, reflecting the dynamic nature of the field. The following areas are gaining prominence in recent publications, demonstrating the journal's responsiveness to evolving challenges and advancements in cancer care.
  1. Immunotherapy and Combination Treatments:
    A significant increase in studies exploring the efficacy of immunotherapies, particularly in combination with other treatment modalities, highlights the growing interest in harnessing the immune system to combat cancer.
  2. Real-World Evidence and Patient Outcomes:
    There is a notable trend towards incorporating real-world evidence in oncology research, focusing on patient outcomes, treatment adherence, and the impact of socio-economic factors on cancer care.
  3. Health Equity and Access to Care:
    Emerging research emphasizes the importance of addressing health disparities, with a focus on improving access to cancer care for underrepresented populations and in low-resource settings.
  4. Precision Medicine and Genomics:
    A rising trend in the application of genomic profiling and precision medicine approaches is evident, with studies exploring how genetic insights can guide tailored cancer therapies.
  5. Environmental and Societal Impacts on Cancer Outcomes:
    Research examining the effects of environmental factors, lifestyle changes, and public health policies on cancer incidence and outcomes is becoming increasingly relevant in the journal.

Declining or Waning

While LANCET ONCOLOGY continues to cover a broad spectrum of oncology research, some themes have seen a decline in prominence. This may reflect shifts in research focus, changing clinical priorities, or advancements in specific areas that have led to saturation.
  1. Traditional Chemotherapy Approaches:
    As newer therapies such as immunotherapy and targeted treatments gain traction, traditional chemotherapy regimens are discussed less frequently, indicating a potential shift in treatment paradigms.
  2. Single-Agent Drug Studies:
    There has been a noticeable decrease in studies focusing solely on single-agent chemotherapy drugs, as combination therapies and multi-drug regimens are increasingly favored for their improved efficacy.
  3. Local Treatment Modalities:
    Research on localized treatment modalities, such as traditional surgery and radiotherapy alone, appears to be waning as the focus shifts towards integrated approaches that combine systemic therapies.
  4. Conventional Diagnostic Techniques:
    The rise of advanced imaging techniques and liquid biopsies has resulted in a decline in the publication of studies centered on conventional diagnostic methods like biopsy and standard imaging.
  5. Basic Science Research in Oncology:
    There is a diminishing focus on basic science research unrelated to clinical applications, as the journal prioritizes translational research that directly impacts patient care.

Similar Journals

JAMA Oncology

Pioneering insights in oncology and cancer treatment.
Publisher: AMER MEDICAL ASSOCISSN: 2374-2437Frequency: 12 issues/year

JAMA Oncology, published by the American Medical Association, stands at the forefront of cancer research as a premier peer-reviewed journal in the field. With an ISSN of 2374-2437 and an impressive impact factor reflecting its critical insights, the journal has achieved a top-tier position, being ranked in the Q1 quartile for both Cancer Research and Oncology as of 2023, and demonstrating exceptional performance in Medicine as well. Spanning a converged publication period from 2015 through 2024, JAMA Oncology publishes cutting-edge research, clinical trials, and reviews that are pivotal in advancing our understanding and treatment of cancer. The journal's Scopus ranks highlight its global impact, placing it in the top deciles within its categories, ensuring that it remains a vital resource for oncologists, researchers, and students alike. While it currently does not offer open access, JAMA Oncology continues to provide invaluable contributions to the scientific community, promoting a deeper understanding of oncological challenges and breakthroughs.

South Asian Journal of Cancer

Connecting researchers for a cancer-free future.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

eCancerMedicalScience

Fostering insights for a world free of cancer.
Publisher: eCancer Global FoundationISSN: 1754-6605Frequency:

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

BREAST

Fostering collaboration for improved patient outcomes.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

CANCER

Unveiling breakthroughs in oncology since 1948.
Publisher: WILEYISSN: 0008-543XFrequency: 24 issues/year

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

INDIAN JOURNAL OF CANCER

Empowering Cancer Research, Inspiring Change
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

JNCI-Journal of the National Cancer Institute

Unveiling the complexities of cancer for better outcomes.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

International Journal of Clinical Oncology

Leading the Charge in Oncology Research Excellence
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

CANCER INVESTIGATION

Advancing cancer research, one investigation at a time.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Cancer Management and Research

Pioneering new paths in cancer management and research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.